Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation

With improved therapeutic options, people with CF have experienced greater quality and quantity of life. Consequently, more women with CF have expressed interest in pregnancy [1]. Between 1998 and 2018, pregnancies in women with CF in the U.S. doubled from 140 to 280, and peaked at 310 in 2019 [2]. Based on previous work demonstrating further increases in pregnancy rates following the approval of CFTR modulator therapy [3], the number of pregnancies with CF will likely continue to increase.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Source Type: research